抗EGFR单链抗体融合Gelonin免疫毒素与紫杉醇协同抗肿瘤作用及机制研究
Synergistic Cytotoxic Effect of Anti-EGFR/Gelonin Immunotoxin Combined with Taxol Anti-Tumor Effects and Its Mechanism

作者: 黄浓郁 , 周西坤 , 邱 吉 , 王 振 , 李 炯 :四川大学华西医院生物治疗国家重点实验室,成都;

关键词: 抗EGFR单链抗体融合Gelonin免疫毒素紫杉醇表皮生长因子受体肿瘤协同作用Anti-EGFR/Gelonin Immunotoxin Taxol EGFR Tumor Synergistic Effect

摘要:

目的:研究抗EGFR单链抗体融合gelonin免疫毒素(E/rG)与紫杉醇是否具有协同抗肿瘤作用,进一步探讨两种药物联合作用产生协同效应的机制。方法:在体外实验中,利用MTT方法研究两种药物联合抑制EGFR阳性癌细胞的生物学效应;在体内试验中,建立人肺癌A549细胞裸鼠移植瘤模型,两种药物联合治疗评价两者的协同抗肿瘤作用。利用ELISA检测紫杉醇单独给药治疗后小鼠血清和肿瘤ECF中的EGFR水平。结果:在体外未检测到E/rG免疫毒素与紫杉醇的协同作用,在体内检测到两种药物具有显著的协同作用。ELISA检测结果显示紫杉醇治疗能够降低小鼠血清和肿瘤ECF中的EGFR水平。结论:在体外实验中,未发现两种药物协同抑制肿瘤细胞生长的作用,而在体内实验中,两种药物具有显著的协同抗肺癌肿瘤作用,其作用机制是紫杉醇给药后降低了小鼠血液中和肿瘤组织间隙液中的游离EGFR含量,减少了游离EGFR对免疫毒素的靶向抗肿瘤作用的影响。为抗EGFR单链抗体融合gelonin免疫毒素临床使用方案具有重要的指导意义。

Abstract: Iron is an essential element for cell growth. The iron contents in tumor cells are higher than those in normal cells. The addition of exogenous iron can prevent apoptosis while iron chelators can inhibit the growth of tumor cells. Therefore, the anti-tumor effect of iron chelators obtains more and more extensive concern. This article aims to present a review on recent advancements in studies of iron and cervical cancer, and to explore the mechanism of iron in initiating cervical cancer as well as the effects of iron chelators on treatment of cervical cancer.

文章引用: 黄浓郁 , 周西坤 , 邱 吉 , 王 振 , 李 炯 (2014) 抗EGFR单链抗体融合Gelonin免疫毒素与紫杉醇协同抗肿瘤作用及机制研究。 世界肿瘤研究, 4, 4-9. doi: 10.12677/WJCR.2014.41002

参考文献

[1] Hassan, R., Broaddus, V.C., Wilson, S., et al. (2007) Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts. Clinical Cancer Research, 13, 7166-7171.

[2] Hsu, C.H., Kang, Y.K., Yang, T.S., et al. (2013) Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study. Oncology, 85, 44-52.

[3] Kreitman, R.J. (2009) Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. BioDrugs, 23, 1-13.

[4] Li, Y.M. and Hall, W.A. (2010) Targeted toxins in brain tumor therapy. Toxins (Basel), 2, 2645-2662.

[5] FitzGerald, D.J., Wayne, A.S., Kreitman, R.J., et al. (2011) Treatment of hematologic malignancies with immunotoxins and an-tibody-drug conjugates. Cancer Research, 71, 6300-6309.

[6] Ira, P., Raffit, H., David, J., et al. (2007) Immunotoxin treatment of cancer. Annual Review of Medicine, 58, 221-237.

[7] Karamouzis, M.V., Grandis, J.R. and Argiris, A. (2007) Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. The Journal of the American Medical Association, 298, 70-82.

[8] 邱吉, 李倩, 李小磊等 (2011) 抗EGFR单链抗体融合gelonin毒素的原核表达载体的构建及其生物活性研究. 四川大学学报(医学版), 42, 621-624.

[9] Zhou, X., Qiu, J., Wang, Z., et al. (2012) In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin. Cancer Research and Clinical Oncology, 138, 1081-1090.

[10] 徐淑萍, 孙国平, 王华等 (2006) 丹皮酚增强顺铂对人肝癌细胞SMMC-7721的增殖抑制作用. 安徽医科大学学报, 41, 63-65.

[11] 金正均 (1980) 合并用药中的相加. 中国药理学报, 1, 70-73.

[12] Zhang, Y.J., Xiang, L.M., Raffit, H., et al. (2007) Immunotoxin and Taxol synergy results froma decrease in shed mesothelin levels in the extracellular space of tumors. Proceedings of the National Academy of Sciences of the USA, 104, 17099-17104.

[13] 甄永苏 (2007) 抗体药物与肿瘤靶向治疗. 医学研究杂志, 36, 1-2.

[14] Chauhan, V.P., Stylianopoulos, T., Boucher, Y., et al. (2011) Delivery of molecular and nanoscale medicine to tumors: Transport barriers and strategies. Annual Review of Chemical and Biomolecular Engineering, 2, 281-298.

[15] Multhoff, G. and Vaupel, P. (2012) Radiation-induced changes in microcirculation and interstitial fluid pressure affecting the delivery of macromolecules and nanotherapeutics to tumors. Frontiers in Oncology, 15, 165.

[16] Zhang, Y., Xiang, L., Hassan, R., et al. (2006) Synergistic antitumor activity of Taxol and immunotoxin SS1P in tumor-bearing mice. Clinical Cancer Research, 12, 4695-4701.

[17] Du Bois, A., Huober, J., Stopfer, P., et al. (2010) A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. Annals of Oncology, 21, 370-375.

分享
Top